tau imaging news changes Alzheimer's workups by adding a new tau PET choice and clearer result questions for primary care. Tau means twisted protein tangles inside brain cells that track memory loss. Primary care patients can now ask what a positive scan proves, who qualifies, and where blood tests fit. The answers affect referrals, scan timing, and next steps after cognitive complaints.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does a positive tau scan show?
- Who qualifies for the new scan?
- Why does the newer tracer find more tau?
- Why can tau signals mislead?
- Where does blood testing fit before PET?
What does a positive tau scan show?
A tau PET scan looks for tau tangle pathology in the living brain. Tangles are dense tau fibers that injure nerve cells. Lantheus reports in the FDA approval notice that TAUKLARIFY was approved to identify that pathology in adults with cognitive impairment being evaluated for Alzheimer's disease.
A positive result does not stand alone. Practical Neurology reports labeling positions tau PET as complementary to amyloid PET and other biomarkers. Practical Neurology also reports tangles confined to the medial temporal lobe count as positive.
Who qualifies for the new scan?
The labeled group is narrow. It covers cognitively impaired adults undergoing Alzheimer's evaluation. It does not cover routine screening in people without thinking changes.
Limits matter for families facing other diagnoses. Pharmacy Times reports safety and effectiveness are not established for non-Alzheimer's tauopathies. A positive scan therefore does not diagnose progressive supranuclear palsy, frontotemporal dementia, or other tau diseases.
Why does the newer tracer find more tau?
Some older scans miss early tau. University of Pittsburgh researchers reported through MedicalXpress in the HEAD study report that 682 participants received both MK-6240 and standard flortaucipir, with MK-6240 positive more than twice as often in unimpaired amyloid-positive people, 15% versus 6%.
Being Patient reports the newer tracer better separated Alzheimer's impairment with both amyloid and tau from non-Alzheimer's impairment. Earlier signals may allow earlier detection and more accurate staging than flortaucipir alone. Earlier is not always simpler, because mild signals need clinical context.
Why can tau signals mislead?
Scan brightness is not always tau. UCSF researchers combined tau PET with postmortem brain mapping in an Acta Neuropathologica study. MedicalXpress reports some flortaucipir signal in non-Alzheimer's cases fit iron and MAO-B-related off-target binding better than tau. That finding raises practical questions for primary care reads.
Was amyloid also present. Did symptoms match an Alzheimer's pattern. Would a movement disorder, language change, or behavioral shift point elsewhere. Psychiatric Times reports approval testing used blinded image reads across more than 500 participants, with positive reader agreement of 80%-88% in one study and 68%-82% in the other.
Where does blood testing fit before PET?
Many workups may start with blood, not scans. Roche announced in the Elecsys pTau217 update FDA clearance on Aug.
24, 2026 for adults 55 and older with cognitive complaints as the first single-biomarker blood test to both rule-in and rule-out amyloid pathology with the same cutoffs in primary and specialty care. Patients can use that sequence to plan a primary care visit: Bring a list of memory examples, onset dates, and current medicines to that visit.
- Ask whether symptoms meet criteria for cognitive impairment.
- Ask whether an amyloid blood result should come before PET.
- Ask how medial-temporal tau would change diagnosis or referrals.
- Ask what other causes could explain memory or thinking changes.
You Might Also Like
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Result Interpretation Questions for Primary Care Patients
- The NIA 2026 Dementia Care and Caregiving Summit Report: Questions Long-Distance Caregivers Can Ask Local Care Programs
- Strengths-Based Dementia Care in the 2026 NIA Report: Questions Long-Distance Caregivers Can Ask Local Care Programs
